Clinical Trials in Germany

• Phase IIB Study of PHENOGENE-1A (Cromolyn) as an Adjuvant Therapy in Mild to Moderate ALS Recruiting
  2025-520688-42-00 Phase II Amyotrophic Lateral Sclerosis (ALS) Phenonet Inc.
• A Phase 2/3 clinical trial with zanzalintinib versus everolimus Recruiting
  2025-521043-20-00 Phase II/III Neuroendocrine tumors Exelixis Inc.
• A clinical study to test if an investigational treatment called BNT314 when used in combination with another investigational treatment pumit… Recruiting
  2025-521768-36-00 Phase I/II Metastatic colorectal cancer BioNTech SE
• Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or Af… Recruiting
  2025-522400-24-00 Phase II/III Metastatic urothelial cancer Bristol-Myers Squibb Services Unlimited Company
• A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants Recruiting
  2025-523995-21-00 Phase I (Other) Healthy participants AstraZeneca AB
• A Randomized controlled open-label phase II trial assessing the efficacy and safety of two-dosing regimens of frozen encapsulated fecal micr… Recruiting
  2024-519748-34-00 Phase II Infections with multidrug-resistant Enterobacteriaceae Goethe University Frankfurt
• Brivekimig for the treatment of moderate to severe hidradenitis suppurativa Recruiting
  2025-522333-61-00 Phase II Hidradenitis suppurativa Sanofi-Aventis Recherche & Developpement
• A Study in Adults with Parkinson's Disease and a Lack of Interest or Motivation to Test How Different Doses of IRL757 Given for Multiple Day… Recruiting
  2025-523612-37-00 Phase I (Other) Parkinson's Disease and Apathy Integrative Research Laboratories Sweden AB
• Randomized Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carc… Recruiting
  2024-515023-11-00 Phase III Advanced Clear Cell Renal Cell Carcinoma Arcus Biosciences Inc.
• Phase 1b/2a Study to Evaluate Mezigdomide in Combination with Elranatamab in Relapsed and/or Refractory Multiple Myeloma Recruiting
  2025-522090-11-00 Phase I/II Relapsed or Refractory Multiple Myeloma (RRMM) Celgene Corp.
• An open label, phase I/II study investigating the safety and efficacy of the bispecific T-cell engaging antibody cizutamig (BCMAxCD3) in pat… Recruiting
  2025-522857-20-00 Phase I/II Severe, treatment refractory primary Sjögren’s disease (pSjD… Fraunhofer Institute For Translational Medicine And Pharmacology ITMP
• Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting
  2024-515658-26-00 Phase III Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS… Daiichi Sankyo Inc.
• A Study of Amivantamab in Addition to Standard of Care Agents Compared with Standard of Care in Participants With Recurrent/Metastatic Head … Recruiting
  2025-521917-24-00 Phase III Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous … Janssen Cilag International
• BEAT-GVHD (Belumosudil for acute/chronic GVHD overlap syndrome) Recruiting
  2025-521940-39-00 Phase II steroid-refractory overlap syndrom Graft-versus-Host-Disease Medical Center - University Of Freiburg
• Randomized Evaluation of Treosulfan versus Melphalan conditioning fol-lowed by PTCY in Patients with AML and MDS undergoing allogeneic Trans… Recruiting
  2023-507879-21-00 Phase II AML and MDS undergoing allogeneic Transplantation Technische Universitat Dresden
• A study to learn about how well BAY 3401016 works in adults with Alport syndrome Recruiting
  2024-516471-33-00 Phase II Alport Syndrome Bayer AG
• A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA Recruiting
  2025-521530-28-00 Phase I/II Progressive systemic autoimmune disease resistant to B cell … Universitaetsklinikum Erlangen AöR
• ​​Vorasidenib for the treatment of IDH-mutant astrocytoma after standard chemoradiotherapy Recruiting
  2024-519404-27-00 Phase III ​​IDH-mutant grade 2 or 3 astrocytoma​ Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europ…
• A Phase 3 Study of JNT-517 in Participants with Phenylketonuria Recruiting
  2024-519554-37-00 Phase III Phenylketonuria Otsuka Pharmaceutical Development & Commercialization Inc.
• An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with S… Recruiting
  2024-520208-25-00 Phase II Still’s disease Novartis Pharma AG
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 Phase III Early-Stage Parkinson’s Disease (PD) F. Hoffmann-La Roche AG
• Pharmacokinetics, pharmacodynamics, safety, and tolerability of an acetonic milk thistle extract, standardized to silymarin, in subjects wit… Recruiting
  2025-522423-95-00 Phase I (Other) chronic liver disease Bionorica SE
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee ( ATTAIN-OA PAIN ) Recruiting
  2025-522631-34-00 Phase III Osteoarthritis Eli Lilly & Co.
• A study to compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 with US-Dupixent®, and EU-Dupixent® in Healt… Recruiting
  2025-523115-11-00 Phase I Phase I study in healthy participants. Intended indication: … Chong Kun Dang Pharmaceutical Corp.

Showing 841–864 of 3,914 trials